racemetyrosine (SM-88) / Syros 
Welcome,         Profile    Billing    Logout  
 0 Diseases   5 Trials   5 Trials   276 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
racemetyrosine (SM-88) / Syros
NCT04229004: A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Active, not recruiting
3
825
US
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Pancreatic Cancer Action Network
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
06/27
06/27
HopES, NCT03778996: SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

Active, not recruiting
2
31
US
Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), SM-88
Sarcoma Oncology Research Center, LLC, Tyme, Inc
Sarcoma, Ewing, Sarcoma
12/24
03/25
OASIS, NCT04720664: Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

Terminated
2
11
US
SM-88
Georgetown University, Tyme, Inc
Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma
02/23
02/23

Download Options